ILR to Prevent BRCL_MCC 23608

Recruiting now · Not applicable

Conditions studied: Breast Cancer Lymphedema

In brief

The goal of this clinical trial is to evaluate the effectiveness of Immediate Lymphatic Reconstruction (ILR) in preventing breast cancer-related lymphedema (BCRL) in high-risk patients. It will also assess the safety and quality of life outcomes associated with the procedure. The main questions it aims to answer are: Does ILR reduce the incidence of BCRL in patients undergoing axillary lymph node dissection (ALND)? What are the patient-reported outcomes and quality of life differences between those who receive ILR and those who do not? Participants will be identified as high-risk for developing BCRL through a multidisciplinary tumor board and referred to a specialized clinic for further evaluation. High-risk patients will undergo a series of screening tests, including bioimpedance spectroscopy (BIS), circumferential limb measurements, and infrared 3D perometry. Participants will be randomly assigned to one of two groups: Intervention Group (Study Arm A): Undergo ILR during ALND surgery, where preserved lymphatic channels are connected to nearby veins to prevent lymphedema. Control Group (Study Arm B): Will not receive ILR, but efforts will be made to preserve lymphatic channels during surgery. Patients will be blinded to their group assignment. Post-surgery, all participants will receive education from a certified lymphatic physical therapist. At the 2-week postoperative visit, participants will be further randomized into two postoperative monitoring protocols: BCRL Clinical Pathway: Patients will have regular follow-up visits every three months for two years, including repeat BIS, limb measurements, perometry, and quality of life questionnaires (LYMQOL and ULL-27). Standard of Care: Patients will be monitored only if they experience BCRL symptoms or after two years from ALND. The study will compare the outcomes of both groups, with a focus on the incidence of BCRL and patient quality of life, and will benchmark these results against published literature on breast cancer patients.

Key facts

Study ID: NCT07127003
Run by: University of South Florida
People needed: 98
Starts: 2025-10-01
Expected to finish: 2027-10-01
Last updated by the study team: 2026-04-30

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Patients consenting for unilateral ALND [prior history of sentinel lymph node biopsy (SLNBx) allowed if <6 months from consent]
Patients consenting for unilateral SLNBx with possible ALND, with a clinically or radiographically positive lymph node OR a high likelihood of ALND per the Breast Surgeon
Identification of at least one transected lymphatic channel and at least one vein to be used for bypass at the time of ALND during surgery
Female breast cancer patients 18-75 years of age (inclusive)

You may not qualify if…

• Male breast cancer patients
Non-English speaking participants
Female breast cancer patients with axillary recurrence
Female breast cancer patients who have a history of ALND
Female patients requiring bilateral ALND for the treatment of their breast cancer
Female breast patients treated with SLNBx only
Primary lymphedema of the affected upper limb
Secondary lymphedema of the affected limb prior to the lymphadenectomy
Radiotherapy at the axilla before the study / surgery
Life expectancy < 2 years for any reason
Pregnancy or nursing
Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening
Severe psychiatric disease
Distant metastases at the time of preoperative screening

Where it is running

Tampa General Hospital — Tampa, Florida, United States (enrolling)
Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
University of South Florida — Tampa, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.